Home / Stocks / Stock Alert: Hoth Therapeutics Gains 110% Following Deal With Voltron

Stock Alert: Hoth Therapeutics Gains 110% Following Deal With Voltron

(RTTNews) – Shares of Hoth Therapeutics, Inc. (HOTH) are climbing more than 110% Monday morning after the company announced its deal with Voltron Therapeutics, Inc. to jointly develop Self-Assembling Vaccine (SAV) for the prevention of the COVID-19.

Hoth Therapeutics and Voltron are to form HaloVax, a joint venture company to commence preclinical studies for the development of vaccine to prevent coronavirus based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital.

As per the deal, Hoth will be given the right to receive single digit royalties from the sale of any products developed, and to acquire up to a 30% equity interest in HaloVax.

Dr. Michael Callahan, Chief of Translational Medicine, Vaccine and Immunotherapy Center, of MGH said, “We believe this SAV technology developed at the VIC, which has proof of concept data in infectious diseases and oncology in four animal models, has the potential to assist in the rapid development and testing of products to prevent, intercept or treat COVID-19.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

300-101   400-101   300-320   300-070   300-206   200-310   300-135   300-208   810-403   400-050   640-916   642-997   300-209   400-201   200-355   352-001   642-999   350-080   MB2-712   400-051   C2150-606   1Z0-434   1Z0-146   C2090-919   C9560-655   642-64   100-101   CQE   CSSLP   200-125   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-075   300-115   AWS-SYSOPS   640-692   640-911   1Z0-144   1z0-434   1Z0-803   1Z0-804   000-089   000-105   70-246   70-270   70-346   70-347   70-410